THE POSITION WE OFFER:
Senior Manager – Oracle Fusion SCM & Analytics – CDI permanent position - Based in Paris 13ème
About the role:
Cellectis is seeking a Senior Manager – Oracle Fusion SCM & Analytics to lead the delivery, stabilization, and continuous evolution of Oracle Fusion Supply Chain Management and Analytics solutions.
This is a senior individual contributor role with end‑to‑end accountability for functional design, solution quality, and operational reliability. While the role does not include people management, it carries significant functional leadership, influence, and decision‑making responsibility across business stakeholders, system integrators, and IT governance forums.
You will operate at the intersection of IT, business operations, and compliance within a highly regulated biopharmaceutical environment.
Missions:
• Oracle Fusion SCM Ownership - Act as the functional owner for Oracle Fusion SCM modules (Inventory Management, Procurement, Order Management, …). Lead the design, configuration, and evolution of SCM solutions aligned with business objectives. Ensure robust, scalable, and compliant implementations across all SCM domains.
• Oracle Fusion Analytics & Insights – Build and own the functional roadmap for Oracle Fusion Analytics and OTBI for SCM, Finance and operations. Define KPIs, dashboards, and analytical use cases with business leaders. Ensure data accuracy, reconciliation, and audit‑ready reporting. Support decision‑making through reliable operational and management insights.
• Strategic Business Partnering - Serve as the senior functional interface between Supply Chain, Manufacturing, Quality and Finance internal stakeholders and external Oracle system integrators and vendors. Lead business workshops, solution design sessions, and validation reviews. Translate complex business needs into clear, actionable Oracle Fusion solutions. Provide functional leadership without direct line management responsibilities.
• Operations, Releases & Compliance - Contribute to production support for SCM, analytics and financial solutions, operating within an ITSM framework (incident, problem, and change management). Ensure solution stability, continuous improvement, and user adoption post go‑live. Enforce IT governance, documentation, and change control standards aligned with SOX and GxP requirements. Support audit readiness, internal controls, and regulatory inspections when ERP systems are in scope. Apply Computer System Validation (CSV) principles were required (knowledge strongly preferred).
Un mot du manager :
“ Dans notre équipe, nous travaillons dans un environnement familial et bienveillant, idéal pour débuter et progresser. Notre service maintenance est à taille humaine. L’accompagnement, la transmission des compétences et l’esprit d’équipe sont au cœur du quotidien. Enfin, nous prenons le temps de célébrer les étapes que nous franchissons !”
PROFILE & QUALIFICATIONS :
Experience:
• 8–12+ years of experience with Oracle applications, including strong expertise in Oracle Fusion SCM.
• Demonstrated experience leading Oracle Fusion implementations and post go live operations.
• Strong understanding of end to end supply chain processes and integration with Finance.
• Proven experience acting as a senior functional lead without people management.
• Exposure to Oracle Fusion Analytics / OTBI.
Professional strengths
• Comfortable operating at senior manager / expert level with executive level stakeholders.
• Strong communication, influencing, and stakeholder management skills.
• Structured, pragmatic, and delivery driven mindset.
• Ability to challenge solutions constructively while remaining business oriented.
Environment
• Experience in regulated environments (biotech, pharma, life sciences).
• Familiarity with ITSM tools and processes.
• Fluent in English & French.
THE CONDITIONS WE OFFER:
• Innovative projects and a collaborative working environment
• A competitive compensation package based on annual “SMART” objectives
• Tailored employee benefits coverage for you and your family
• An on-site company restaurant
• A modern and pleasant work environment featuring relaxation areas, a gym, terraces, and a kitchen garden
• A very active Works Council (CSE) offering a wide range of employee benefits (internal media library, seated massages, cultural and sports subsidies, etc.)
• Regular internal events
Cellectis is a global clinical-stage biopharmaceutical company. Pioneers and innovators in our field, our mission is to develop innovative treatments for patients with unmet medical needs.
With 25 years of expertise, we have the best-in-class gene editing platform focusing on immuno-oncology, and gene therapy. Through our efficient and precise TALEN® technology, we create allogeneic CAR-T cells capable of recognizing and combating cancer cells.
Today, our two* clinical programs target patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL).
We are fully integrated and a leader in end-to-end gene editing, allogeneic CAR T-cell companies. With our in-house manufacturing, we control our gene and cell therapy process from start to finish with starting materials produced in Paris (France) and CAR-T therapy products created in Raleigh, NC.
We also have several ongoing strong collaborations, based on our TALEN® technology, with leading cell & gene therapy companies, including our recent partnership with AstraZeneca, to develop new product candidates in oncology, immunology, and treatment of rare diseases.
At Cellectis, we are committed to a cure.
Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
To find out more about us, visit our website: www.cellectis.com. To learn more about our community guidelines, visit: http://www.cellectis.com/en/social-media-guidelines/
Follow our other social media account on X.
(*) On November 4, 2024, Cellectis decided to focus its current development efforts on the BALLI-01 and NATHALI-01 studies and therefore to deprioritize the development of UCART123.
TALEN® is a registered trademark owned by the Cellectis Group.
